
Nektar Therapeutics, an American healthcare company, innovates polymer-based therapeutics.
Nektar Therapeutics, founded in the United States, is dedicated to developing innovative polymer-based therapeutics. The company's core mission is to bring hope to millions of patients by creating new medicines that address serious medical needs. Nektar leverages its advanced polymer conjugate chemistry technology platform to optimize therapeutic benefits. Their product focus includes novel therapies for autoimmune disorders, chronic inflammatory conditions, and cancer, aiming to selectively modulate the immune system and restore its balance.
Notable figures affiliated with Nektar Therapeutics include key scientists and executives who have significantly contributed to the field of polymer chemistry and drug development. The company has attracted substantial investment from leading healthcare investors and has achieved several milestones, including successful clinical trials and regulatory approvals for its therapies. Nektar's impact is evident in its contribution to advancing treatment options for complex diseases, offering new hope and improved outcomes for patients worldwide.

NKT Therapeutics

NeuroTherapeutics Pharma

Neurona Therapeutics

Nerx Biosciences

Kymera Therapeutics
kymeratx.com

Neutrolis
neutrolis.com

Nested Therapeutics
nestedtx.com

NeuroTherapia
neurotherapia.com

Neuraptive Therapeutics
neuraptive.com

Neuropathix
neuropathix.com

Modulus Therapeutics

Pliant Therapeutics
pliantrx.com

Akttyva Therapeutics
akttyva.com

Acorda Therapeutics
acorda.com

Nantkwest
Companies similar to Nektar Therapeutics include NKT Therapeutics, NeuroTherapeutics Pharma, Neurona Therapeutics and Nerx Biosciences.
Nektar Therapeutics was founded in 1990.
Nektar Therapeutics' headquarters is located in San Francisco, CA, US.
Nektar Therapeutics' most recent funding round was for $150M (USD) in February 2021.
As of Feb 17, 2021, Nektar Therapeutics has raised a total of $1.2B (USD).
Nektar Therapeutics has 216 employees as of Feb 6, 2024.